Connection

Francis Spinale to Animals

This is a "connection" page, showing publications Francis Spinale has written about Animals.
Connection Strength

2.727
  1. Regional heterogeneity in determinants of atrial matrix remodeling and association with atrial fibrillation vulnerability postmyocardial infarction. Heart Rhythm. 2022 05; 19(5):847-855.
    View in: PubMed
    Score: 0.059
  2. Ubiquitin ligase Wwp1 gene deletion attenuates diastolic dysfunction in pressure-overload hypertrophy. Am J Physiol Heart Circ Physiol. 2021 11 01; 321(5):H976-H984.
    View in: PubMed
    Score: 0.058
  3. The ubiquitin ligase WWP1 contributes to shifts in matrix proteolytic profiles and a myocardial aging phenotype with diastolic heart. Am J Physiol Heart Circ Physiol. 2020 10 01; 319(4):H765-H774.
    View in: PubMed
    Score: 0.054
  4. Heart failure as interstitial cancer: emergence of a malignant fibroblast phenotype. Nat Rev Cardiol. 2020 08; 17(8):523-531.
    View in: PubMed
    Score: 0.051
  5. Regional and temporal changes in left ventricular strain and stiffness in a porcine model of myocardial infarction. Am J Physiol Heart Circ Physiol. 2018 10 01; 315(4):H958-H967.
    View in: PubMed
    Score: 0.046
  6. Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling. Am J Physiol Heart Circ Physiol. 2018 10 01; 315(4):H814-H825.
    View in: PubMed
    Score: 0.046
  7. Institution of localized high-frequency electrical stimulation targeting early myocardial infarction: Effects on left ventricle function and geometry. J Thorac Cardiovasc Surg. 2018 08; 156(2):568-575.
    View in: PubMed
    Score: 0.045
  8. Intracoronary delivery of recombinant TIMP-3 after myocardial infarction: effects on myocardial remodeling and function. Am J Physiol Heart Circ Physiol. 2017 Oct 01; 313(4):H690-H699.
    View in: PubMed
    Score: 0.043
  9. In vivo assessment of regional mechanics post-myocardial infarction: A focus on the road ahead. J Appl Physiol (1985). 2017 Oct 01; 123(4):728-745.
    View in: PubMed
    Score: 0.042
  10. Crossing Into the Next Frontier of Cardiac Extracellular Matrix Research. Circ Res. 2016 10 28; 119(10):1040-1045.
    View in: PubMed
    Score: 0.041
  11. Sonomicrometry-Based Analysis of Post-Myocardial Infarction Regional Mechanics. Ann Biomed Eng. 2016 12; 44(12):3539-3552.
    View in: PubMed
    Score: 0.040
  12. Assessment of Cardiac Function--Basic Principles and Approaches. Compr Physiol. 2015 Sep 20; 5(4):1911-46.
    View in: PubMed
    Score: 0.038
  13. Cardiac-restricted overexpression or deletion of tissue inhibitor of matrix metalloproteinase-4: differential effects on left ventricular structure and function following pressure overload-induced hypertrophy. Am J Physiol Heart Circ Physiol. 2014 Sep 01; 307(5):H752-61.
    View in: PubMed
    Score: 0.035
  14. Targeting matrix metalloproteinases in heart disease: lessons from endogenous inhibitors. Biochem Pharmacol. 2014 Jul 01; 90(1):7-15.
    View in: PubMed
    Score: 0.035
  15. Targeted overexpression of tissue inhibitor of matrix metalloproteinase-4 modifies post-myocardial infarction remodeling in mice. Circ Res. 2014 Apr 25; 114(9):1435-45.
    View in: PubMed
    Score: 0.034
  16. Local hydrogel release of recombinant TIMP-3 attenuates adverse left ventricular remodeling after experimental myocardial infarction. Sci Transl Med. 2014 Feb 12; 6(223):223ra21.
    View in: PubMed
    Score: 0.034
  17. Myocardial fibroblast-matrix interactions and potential therapeutic targets. J Mol Cell Cardiol. 2014 May; 70:92-9.
    View in: PubMed
    Score: 0.034
  18. Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ Heart Fail. 2014 Mar 01; 7(2):340-50.
    View in: PubMed
    Score: 0.034
  19. Integrating the myocardial matrix into heart failure recognition and management. Circ Res. 2013 Aug 30; 113(6):725-38.
    View in: PubMed
    Score: 0.033
  20. Biomarkers and heart disease: what is translational success? J Cardiovasc Transl Res. 2013 Aug; 6(4):447-8.
    View in: PubMed
    Score: 0.033
  21. Epilysin (matrix metalloproteinase-28) joins the matrix metalloproteinase team on the field of postmyocardial infarction remodeling. Circ Res. 2013 Feb 15; 112(4):579-82.
    View in: PubMed
    Score: 0.032
  22. Membrane-associated matrix proteolysis and heart failure. Circ Res. 2013 Jan 04; 112(1):195-208.
    View in: PubMed
    Score: 0.032
  23. Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am J Physiol Cell Physiol. 2013 Mar 01; 304(5):C393-402.
    View in: PubMed
    Score: 0.031
  24. Differential membrane type 1 matrix metalloproteinase substrate processing with ischemia-reperfusion: relationship to interstitial microRNA dynamics and myocardial function. J Thorac Cardiovasc Surg. 2013 Jan; 145(1):267-275, 277.e1-4; discussion 275-7.
    View in: PubMed
    Score: 0.031
  25. Gene targeting in ischemic heart disease and failure: translational and clinical studies. Biochem Pharmacol. 2013 Jan 01; 85(1):1-11.
    View in: PubMed
    Score: 0.031
  26. Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis. Am J Physiol Heart Circ Physiol. 2012 Apr 01; 302(7):H1429-37.
    View in: PubMed
    Score: 0.030
  27. Changes in the myocardial interstitium and contribution to the progression of heart failure. Heart Fail Clin. 2012 Jan; 8(1):7-20.
    View in: PubMed
    Score: 0.030
  28. Diversity of myocardial interstitial proteolytic pathways: gene deletion reveals unexpected consequences. Circulation. 2011 Nov 08; 124(19):2052-5.
    View in: PubMed
    Score: 0.029
  29. Progressive induction of left ventricular pressure overload in a large animal model elicits myocardial remodeling and a unique matrix signature. J Thorac Cardiovasc Surg. 2012 Jan; 143(1):215-23.
    View in: PubMed
    Score: 0.029
  30. Targeted regional injection of biocomposite microspheres alters post-myocardial infarction remodeling and matrix proteolytic pathways. Circulation. 2011 Sep 13; 124(11 Suppl):S35-45.
    View in: PubMed
    Score: 0.029
  31. Myocardial remodeling with aortic stenosis and after aortic valve replacement: mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2012 Mar; 143(3):656-64.
    View in: PubMed
    Score: 0.029
  32. Direct regulation of membrane type 1 matrix metalloproteinase following myocardial infarction causes changes in survival, cardiac function, and remodeling. Am J Physiol Heart Circ Physiol. 2011 Oct; 301(4):H1656-66.
    View in: PubMed
    Score: 0.028
  33. Continuous localized monitoring of plasmin activity identifies differential and regional effects of the serine protease inhibitor aprotinin: relevance to antifibrinolytic therapy. J Cardiovasc Pharmacol. 2011 Apr; 57(4):400-6.
    View in: PubMed
    Score: 0.028
  34. Hemodynamics and myocardial blood flow patterns after placement of a cardiac passive restraint device in a model of dilated cardiomyopathy. J Thorac Cardiovasc Surg. 2011 Nov; 142(5):1038-45.
    View in: PubMed
    Score: 0.028
  35. Myocardial remodeling: cellular and extracellular events and targets. Annu Rev Physiol. 2011; 73:47-68.
    View in: PubMed
    Score: 0.028
  36. Cardiac function and circulating cytokines after endotoxin exposure in neonatal mice. Pediatr Res. 2010 Nov; 68(5):381-6.
    View in: PubMed
    Score: 0.027
  37. Heterogeneity in MT1-MMP activity with ischemia-reperfusion and previous myocardial infarction: relation to regional myocardial function. Am J Physiol Heart Circ Physiol. 2010 Dec; 299(6):H1947-58.
    View in: PubMed
    Score: 0.027
  38. Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J Biol Chem. 2010 Sep 24; 285(39):30316-27.
    View in: PubMed
    Score: 0.027
  39. Amplified bioactive signaling and proteolytic enzymes following ischemia reperfusion and aging: remodeling pathways that are not like a fine wine. Circulation. 2010 Jul 27; 122(4):322-4.
    View in: PubMed
    Score: 0.027
  40. Discordant activation of gene promoters for matrix metalloproteinases and tissue inhibitors of the metalloproteinases following myocardial infarction. J Surg Res. 2012 Jan; 172(1):59-67.
    View in: PubMed
    Score: 0.027
  41. Long-term localized high-frequency electric stimulation within the myocardial infarct: effects on matrix metalloproteinases and regional remodeling. Circulation. 2010 Jul 06; 122(1):20-32.
    View in: PubMed
    Score: 0.027
  42. Spatiotemporal induction of matrix metalloproteinase-9 transcription after discrete myocardial injury. FASEB J. 2010 Oct; 24(10):3819-28.
    View in: PubMed
    Score: 0.026
  43. Short-term disruption in regional left ventricular electrical conduction patterns increases interstitial matrix metalloproteinase activity. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H217-24.
    View in: PubMed
    Score: 0.026
  44. Interstitial plasmin activity with epsilon aminocaproic acid: temporal and regional heterogeneity. Ann Thorac Surg. 2010 May; 89(5):1538-45.
    View in: PubMed
    Score: 0.026
  45. Pathophysiology of myocardial injury and remodeling: implications for molecular imaging. J Nucl Med. 2010 May 01; 51 Suppl 1:102S-106S.
    View in: PubMed
    Score: 0.026
  46. Caspase inhibition modulates left ventricular remodeling following myocardial infarction through cellular and extracellular mechanisms. J Cardiovasc Pharmacol. 2010 Apr; 55(4):408-16.
    View in: PubMed
    Score: 0.026
  47. Temporally and regionally disparate differences in plasmin activity by tranexamic acid. Anesth Analg. 2010 Mar 01; 110(3):694-701.
    View in: PubMed
    Score: 0.026
  48. Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation. 2009 Sep 15; 120(11 Suppl):S220-9.
    View in: PubMed
    Score: 0.025
  49. Cardiac-restricted overexpression of membrane type-1 matrix metalloproteinase in mice: effects on myocardial remodeling with aging. Circ Heart Fail. 2009 Jul; 2(4):351-60.
    View in: PubMed
    Score: 0.025
  50. Large animal models of heart failure: a critical link in the translation of basic science to clinical practice. Circ Heart Fail. 2009 May; 2(3):262-71.
    View in: PubMed
    Score: 0.025
  51. Aprotinin modifies left ventricular contractility and cytokine release after ischemia-reperfusion in a dose-dependent manner in a murine model. Anesth Analg. 2009 Feb; 108(2):399-406.
    View in: PubMed
    Score: 0.024
  52. Targeted myocardial microinjections of a biocomposite material reduces infarct expansion in pigs. Ann Thorac Surg. 2008 Oct; 86(4):1268-76.
    View in: PubMed
    Score: 0.024
  53. Aprotinin exacerbates left ventricular dysfunction after ischemia/reperfusion in mice lacking tumor necrosis factor receptor I. J Cardiovasc Pharmacol. 2008 Oct; 52(4):355-62.
    View in: PubMed
    Score: 0.024
  54. Cardiac-restricted overexpression of extracellular matrix metalloproteinase inducer causes myocardial remodeling and dysfunction in aging mice. Am J Physiol Heart Circ Physiol. 2008 Oct; 295(4):H1394-402.
    View in: PubMed
    Score: 0.023
  55. Aprotinin exerts differential and dose-dependent effects on myocardial contractility, oxidative stress, and cytokine release after ischemia-reperfusion. Ann Thorac Surg. 2008 Aug; 86(2):568-75.
    View in: PubMed
    Score: 0.023
  56. Interruption of endothelin signaling modifies membrane type 1 matrix metalloproteinase activity during ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2008 Feb; 294(2):H875-83.
    View in: PubMed
    Score: 0.022
  57. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007 Oct; 87(4):1285-342.
    View in: PubMed
    Score: 0.022
  58. Differential effects of protein kinase C isoform activation in endothelin-mediated myocyte contractile dysfunction with cardioplegic arrest and reperfusion. Ann Thorac Surg. 2006 Aug; 82(2):664-71.
    View in: PubMed
    Score: 0.020
  59. Protein kinase C isoform activation and endothelin-1 mediated defects in myocyte contractility after cardioplegic arrest and reperfusion. Circulation. 2006 Jul 04; 114(1 Suppl):I308-13.
    View in: PubMed
    Score: 0.020
  60. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation. 2006 Jun 27; 113(25):2919-28.
    View in: PubMed
    Score: 0.020
  61. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006 Nov; 291(5):H2216-28.
    View in: PubMed
    Score: 0.020
  62. Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol. 2006 Apr; 40(4):474-83.
    View in: PubMed
    Score: 0.020
  63. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling. J Cardiovasc Pharmacol. 2006 Feb; 47(2):228-35.
    View in: PubMed
    Score: 0.020
  64. Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res. 2006 Feb 15; 69(3):666-76.
    View in: PubMed
    Score: 0.020
  65. From tadpole tails to transgenic mice: metalloproteinases have brought about a metamorphosis in our understanding of cardiovascular disease. Cardiovasc Res. 2006 Feb 15; 69(3):559-61.
    View in: PubMed
    Score: 0.020
  66. Cardiac support device modifies left ventricular geometry and myocardial structure after myocardial infarction. Circulation. 2005 Aug 30; 112(9):1274-83.
    View in: PubMed
    Score: 0.019
  67. Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation. 2005 Aug 30; 112(9 Suppl):I242-8.
    View in: PubMed
    Score: 0.019
  68. Matrix metalloproteinase-9 gene deletion facilitates angiogenesis after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006 Jan; 290(1):H232-9.
    View in: PubMed
    Score: 0.019
  69. Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol. 2005 May; 20(3):211-6.
    View in: PubMed
    Score: 0.019
  70. Myocardial interstitial matrix metalloproteinase activity is altered by mechanical changes in LV load: interaction with the angiotensin type 1 receptor. Circ Res. 2005 May 27; 96(10):1110-8.
    View in: PubMed
    Score: 0.019
  71. Trafficking of the membrane type-1 matrix metalloproteinase in ischemia and reperfusion: relation to interstitial membrane type-1 matrix metalloproteinase activity. Circulation. 2005 Mar 08; 111(9):1166-74.
    View in: PubMed
    Score: 0.018
  72. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol. 2005 Jan; 288(1):H149-58.
    View in: PubMed
    Score: 0.018
  73. Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res. 2005 May 01; 66(2):410-9.
    View in: PubMed
    Score: 0.018
  74. Caspase inhibition attenuates contractile dysfunction following cardioplegic arrest and rewarming in the setting of left ventricular failure. J Cardiovasc Pharmacol. 2004 Dec; 44(6):645-50.
    View in: PubMed
    Score: 0.018
  75. Effects of deletion of the tissue inhibitor of matrix metalloproteinases-1 gene on the progression of murine thoracic aortic aneurysms. Circulation. 2004 Sep 14; 110(11 Suppl 1):II268-73.
    View in: PubMed
    Score: 0.018
  76. Cell-matrix signaling and thrombospondin: another link to myocardial matrix remodeling. Circ Res. 2004 Sep 03; 95(5):446-8.
    View in: PubMed
    Score: 0.018
  77. Myocyte contractility with caspase inhibition and simulated hyperkalemic cardioplegic arrest. Ann Thorac Surg. 2004 May; 77(5):1684-9; discussion 1689-90.
    View in: PubMed
    Score: 0.017
  78. Modulation of calcium transport improves myocardial contractility and enzyme profiles after prolonged ischemia-reperfusion. Ann Thorac Surg. 2003 Dec; 76(6):2054-61; discussion 2061.
    View in: PubMed
    Score: 0.017
  79. Pharmacologic inhibition of intracellular caspases after myocardial infarction attenuates left ventricular remodeling: a potentially novel pathway. J Thorac Cardiovasc Surg. 2003 Dec; 126(6):1892-9.
    View in: PubMed
    Score: 0.017
  80. A murine model of thoracic aortic aneurysms. J Surg Res. 2003 Nov; 115(1):157-63.
    View in: PubMed
    Score: 0.017
  81. Selective targeting and timing of matrix metalloproteinase inhibition in post-myocardial infarction remodeling. Circulation. 2003 Oct 07; 108(14):1753-9.
    View in: PubMed
    Score: 0.017
  82. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation. 2003 Jun 10; 107(22):2857-63.
    View in: PubMed
    Score: 0.016
  83. Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg. 2003 Mar; 125(3):602-10.
    View in: PubMed
    Score: 0.016
  84. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure. Circ Res. 2003 Feb 07; 92(2):177-85.
    View in: PubMed
    Score: 0.016
  85. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003 Feb 04; 107(4):618-25.
    View in: PubMed
    Score: 0.016
  86. Large animal models of congestive heart failure: a critical step in translating basic observations into clinical applications. J Nucl Cardiol. 2003 Jan-Feb; 10(1):77-86.
    View in: PubMed
    Score: 0.016
  87. Bioactive peptide signaling within the myocardial interstitium and the matrix metalloproteinases. Circ Res. 2002 Dec 13; 91(12):1082-4.
    View in: PubMed
    Score: 0.016
  88. Tissue inhibitor of metalloproteinase-4 deletion in mice impacts maternal cardiac function during pregnancy and postpartum. Am J Physiol Heart Circ Physiol. 2023 01 01; 324(1):H85-H99.
    View in: PubMed
    Score: 0.016
  89. Extracellular degradative pathways in myocardial remodeling and progression to heart failure. J Card Fail. 2002 Dec; 8(6 Suppl):S332-8.
    View in: PubMed
    Score: 0.016
  90. The extracellular matrix: summation. J Card Fail. 2002 Dec; 8(6 Suppl):S349-50.
    View in: PubMed
    Score: 0.016
  91. Matrix Metalloproteinase-Targeted SPECT/CT Imaging for Evaluation of Therapeutic Hydrogels for the Early Modulation of Post-Infarct Myocardial Remodeling. J Cardiovasc Transl Res. 2023 Feb; 16(1):155-165.
    View in: PubMed
    Score: 0.015
  92. Cardiorenal effects of adenosine subtype 1 (A1) receptor inhibition in an experimental model of heart failure. J Am Coll Surg. 2002 May; 194(5):603-9.
    View in: PubMed
    Score: 0.015
  93. TNF-alpha and myocardial matrix metalloproteinases in heart failure: relationship to LV remodeling. Am J Physiol Heart Circ Physiol. 2002 Apr; 282(4):H1288-95.
    View in: PubMed
    Score: 0.015
  94. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res. 2002 Mar 22; 90(5):520-30.
    View in: PubMed
    Score: 0.015
  95. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res. 2002 Mar; 53(4):822-30.
    View in: PubMed
    Score: 0.015
  96. Speckle-Tracking Echocardiography Enables Model-Based Identification of Regional Stiffness Indices in the Left Ventricular Myocardium. Cardiovasc Eng Technol. 2020 04; 11(2):176-187.
    View in: PubMed
    Score: 0.013
  97. Application of Hybrid Matrix Metalloproteinase-Targeted and Dynamic 201Tl Single-Photon Emission Computed Tomography/Computed Tomography Imaging for Evaluation of Early Post-Myocardial Infarction Remodeling. Circ Cardiovasc Imaging. 2019 11; 12(11):e009055.
    View in: PubMed
    Score: 0.013
  98. Basigin Promotes Cardiac Fibrosis and Failure in Response to Chronic Pressure Overload in Mice. Arterioscler Thromb Vasc Biol. 2016 Apr; 36(4):636-46.
    View in: PubMed
    Score: 0.010
  99. Inhibition of class I histone deacetylase activity represses matrix metalloproteinase-2 and -9 expression and preserves LV function postmyocardial infarction. Am J Physiol Heart Circ Physiol. 2015 Jun 01; 308(11):H1391-401.
    View in: PubMed
    Score: 0.009
  100. Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibition. Nat Mater. 2014 Jun; 13(6):653-61.
    View in: PubMed
    Score: 0.009
  101. Reply to "letter to the editor: 'cyclosporin A in left ventricular remodeling after myocardial infarction'". Am J Physiol Heart Circ Physiol. 2014 Mar 01; 306(5):H778-9.
    View in: PubMed
    Score: 0.009
  102. Cyclosporin A in left ventricular remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol. 2014 Jan 01; 306(1):H53-9.
    View in: PubMed
    Score: 0.008
  103. Reproducible porcine model of thoracic aortic aneurysm. Circulation. 2013 Sep 10; 128(11 Suppl 1):S186-93.
    View in: PubMed
    Score: 0.008
  104. Pulmonary artery endothelial cell phenotypic alterations in a large animal model of pulmonary arteriovenous malformations after the Glenn shunt. Ann Thorac Surg. 2013 Oct; 96(4):1442-1449.
    View in: PubMed
    Score: 0.008
  105. Gender differences in non-ischemic myocardial remodeling: are they due to estrogen modulation of cardiac mast cells and/or membrane type 1 matrix metalloproteinase. Pflugers Arch. 2013 May; 465(5):687-97.
    View in: PubMed
    Score: 0.008
  106. Animal models of heart failure: a scientific statement from the American Heart Association. Circ Res. 2012 Jun 22; 111(1):131-50.
    View in: PubMed
    Score: 0.008
  107. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging. 2011 Jul; 4(4):381-91.
    View in: PubMed
    Score: 0.007
  108. Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model. Am J Physiol Heart Circ Physiol. 2010 Jul; 299(1):H114-24.
    View in: PubMed
    Score: 0.007
  109. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010 May 04; 121(17):1912-25.
    View in: PubMed
    Score: 0.007
  110. Cellular phenotype transformation occurs during thoracic aortic aneurysm development. J Thorac Cardiovasc Surg. 2010 Sep; 140(3):653-9.
    View in: PubMed
    Score: 0.007
  111. Differential effects of mechanical and biological stimuli on matrix metalloproteinase promoter activation in the thoracic aorta. Circulation. 2009 Sep 15; 120(11 Suppl):S262-8.
    View in: PubMed
    Score: 0.006
  112. Calpain inhibition preserves myocardial structure and function following myocardial infarction. Am J Physiol Heart Circ Physiol. 2009 Nov; 297(5):H1744-51.
    View in: PubMed
    Score: 0.006
  113. Alterations in aortic cellular constituents during thoracic aortic aneurysm development: myofibroblast-mediated vascular remodeling. Am J Pathol. 2009 Oct; 175(4):1746-56.
    View in: PubMed
    Score: 0.006
  114. Differential effect of wall tension on matrix metalloproteinase promoter activation in the thoracic aorta. J Surg Res. 2010 May 15; 160(2):333-9.
    View in: PubMed
    Score: 0.006
  115. Transforming growth factor-beta signaling in thoracic aortic aneurysm development: a paradox in pathogenesis. J Vasc Res. 2009; 46(2):119-37.
    View in: PubMed
    Score: 0.006
  116. Altered transforming growth factor-beta signaling in a murine model of thoracic aortic aneurysm. J Vasc Res. 2008; 45(6):457-68.
    View in: PubMed
    Score: 0.006
  117. Mitral regurgitation augments post-myocardial infarction remodeling failure of hypertrophic compensation. J Am Coll Cardiol. 2008 Jan 29; 51(4):476-86.
    View in: PubMed
    Score: 0.006
  118. Proteinase systems and thoracic aortic aneurysm progression. J Surg Res. 2007 May 15; 139(2):292-307.
    View in: PubMed
    Score: 0.005
  119. Temporal disparity in the induction of matrix metalloproteinases and tissue inhibitors of metalloproteinases after thoracic aortic aneurysm formation. J Thorac Cardiovasc Surg. 2006 Oct; 132(4):788-95.
    View in: PubMed
    Score: 0.005
  120. Chronic matrix metalloproteinase inhibition following myocardial infarction in mice: differential effects on short and long-term survival. J Pharmacol Exp Ther. 2006 Sep; 318(3):966-73.
    View in: PubMed
    Score: 0.005
  121. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation. 2005 Nov 15; 112(20):3157-67.
    View in: PubMed
    Score: 0.005
  122. Infarct size reduction and attenuation of global left ventricular remodeling with the CorCap cardiac support device following acute myocardial infarction in sheep. Heart Fail Rev. 2005 Jun; 10(2):125-39.
    View in: PubMed
    Score: 0.005
  123. Left ventricular form and function: scientific priorities and strategic planning for development of new views of disease. Circulation. 2004 Oct 05; 110(14):e333-6.
    View in: PubMed
    Score: 0.004
  124. Duality of innate stress responses in cardiac injury, repair, and remodeling. J Mol Cell Cardiol. 2004 Oct; 37(4):801-11.
    View in: PubMed
    Score: 0.004
  125. Targeted overexpression of noncleavable and secreted forms of tumor necrosis factor provokes disparate cardiac phenotypes. Circulation. 2004 Jan 20; 109(2):262-8.
    View in: PubMed
    Score: 0.004
  126. Myocardial remodeling after discrete radiofrequency injury: effects of tissue inhibitor of matrix metalloproteinase-1 gene deletion. Am J Physiol Heart Circ Physiol. 2004 Apr; 286(4):H1242-7.
    View in: PubMed
    Score: 0.004
  127. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003 Aug 05; 108(5):598-604.
    View in: PubMed
    Score: 0.004
  128. Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol. 2003 Jan; 284(1):H122-32.
    View in: PubMed
    Score: 0.004
  129. Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol. 2002 Jun; 282(6):H2324-35.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.